FDA Approves Takeda's Orzeyful, First Narcolepsy Drug Targeting Root Cause
In early August, the FDA approved Orzeyful, the first drug targeting the root cause of narcolepsy type 1. Developed by Takeda, the twice-daily oral medication restores the body's orexin cycle, unlike previous symptom-only treatments. Clinical trials involving 273 adults showed improved wakefulness and reduced cataplexy. Patient Tyler Chapman called it life-changing. The approval opens possibilities for orexin-mimicking drugs in ADHD and Parkinson's. Experts caution that orexin loss isn't universal, and future therapies may combine approaches. Julie Flygare, a trial participant and Project Sleep CEO, celebrated the new treatment modality. The drug marks a new chapter for the narcolepsy community.
Key facts
- FDA approved Orzeyful in early August
- Orzeyful is the first drug to target the root cause of narcolepsy type 1
- The twice-daily oral drug is manufactured by Takeda
- It restores the body's orexin cycle by mimicking the natural chemical
- Approximately 120,000 people in the US have narcolepsy type 1
- Clinical trials involved 273 adults over 12 weeks
- Participants on the drug stayed awake longer and had fewer cataplexy episodes
- Takeda president Julie Kim says it introduces an entirely new class of medicine
Entities
Artists
- Alex Dimitriu
- Julie Kim
- Tyler Chapman
- Andy Plump
- Jerome Siegel
- Julie Flygare
- Claire Wolters
- Amanda Heidt
- Sara Hashemi
Institutions
- Food and Drug Administration (FDA)
- Takeda
- Menlo Park Psychiatry and Sleep Medicine
- Nature
- Forbes
- Project Sleep
- University of California, Los Angeles
- Sierra
- The Body
- Maisonneuve magazine
- Getty Images
Locations
- United States
- Japan
- Los Angeles
- New York City
- Menlo Park